Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXCYTE, INC.MXCT · Entity 6608 | Chief Scientific Officer | April 11, 2022 | March 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXCYTE, INC.
Report date April 11, 2022 · Filed March 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.70 · Expires 2032-04-10 | Direct | 500,000 |
Reported balance
After 2022-04-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-04-11 · Grant · Acquired 500,000 · Balance 500,000 F1: As announced in a press release by the issuer on April 15, 2022, on April 11, 2022 the Issuer awarded a stock option to the Reporting Person as a material inducement to his employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option was granted under the Issuer's 2021 Inducement Plan. However, due to an administrative oversight, the stock option grant was not previously reported on a Form 4 as required and is being reported on this report. F2: 25% of the shares underlying this option vest on April 11, 2023 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.19 · Expires 2033-03-19 | Direct | 120,000 |
Reported balance
After 2023-03-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-20 · Grant · Acquired 120,000 · Balance 120,000 F3: 25% of the shares underlying this option vest on March 20, 2024 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: As announced in a press release by the issuer on April 15, 2022, on April 11, 2022 the Issuer awarded a stock option to the Reporting Person as a material inducement to his employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option was granted under the Issuer's 2021 Inducement Plan. However, due to an administrative oversight, the stock option grant was not previously reported on a Form 4 as required and is being reported on this report.
F2: 25% of the shares underlying this option vest on April 11, 2023 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date.
F3: 25% of the shares underlying this option vest on March 20, 2024 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2023 Filed Mar 21, 2023 20:41 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0001209191-23-020283 · doc4.xml · derivative · entry 2 Sumen Cenk · CIK 0001917133 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-03-19 F3 · derivative.exercise_date: 25% of the shares underlying this option vest on March 20, 2024 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document |
| April 11, 2022 Filed Mar 21, 2023 20:41 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001209191-23-020283 · doc4.xml · derivative · entry 1 Sumen Cenk · CIK 0001917133 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2032-04-10 F1 · date: As announced in a press release by the issuer on April 15, 2022, on April 11, 2022 the Issuer awarded a stock option to the Reporting Person as a material inducement to his employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option was granted under the Issuer's 2021 Inducement Plan. However, due to an administrative oversight, the stock option grant was not previously reported on a Form 4 as required and is being reported on this report. F2 · derivative.exercise_date: 25% of the shares underlying this option vest on April 11, 2023 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.